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In 35 patients suspected of an infectious focus, the outcome 
of scintigraphy with 111ln-labeled autologous leukocytes 
(WBC) and 111ln-labeled human nonspecific immunoglobulin 
G (IgG) was evaluated in a prospective comparative study. 
Clinical, roentgenologic and microbiologic findings were con­
sidered to be proof of the presence of infection or inflamma­
tion. In this group of patients with mainly subacute infections, 
1111n-IgG scintigraphy performed significantly better than 1111n- 
WBC scintigraphy, especially in infections of the locomotor 
system, but also in various soft-tissue infections. Both tech­
niques showed disappointing results in patients with dissem­
inated yersinia infection and in some patients with tuberculo­
sis. Overall sensitivity and specificity was 74% and 100% for 
1111n-IgG scintigraphy and 52% and 78% for 111ln-WBC scin­
tigraphy, respectively.
J Nucl Med 1991: 32:1854-1860
In d iu m -l I l-labeled autologous leukocyte (IMIn-WBC) 
scintigraphy is widely accepted as the standard technique 
for the scintigraphic delineation of infectious and inflam­
matory foci. High accuracy of this imaging procedure has 
been reported, especially in acute infections ( /). However, 
preparation of IMIn-WBC is time-consuming, compli­
cated, and costly. Moreover, obtaining sufTicient viable 
leukocytes is more difficult when the peripheral leukocyte 
count is less than 2 x I0w /liter and practically impossible 
when less than 0.5 x 101' /liter.
Several reports suggested the utility of 11‘In-labeled hu­
man nonspecific polyclonal immunoglobulin G (IgG) scin­
tigraphy for the detection of infectious foci (2-5). Indium-
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1 1 1-IgG is a convenient radiopharmaceutical that can be 
prepared as a kit and labeled in less than 30 min. If the 
performance of m In-IgG scintigraphy would be equal or 
better than that of '"In-WBC scintigraphy, adequate im­
aging of focal infection and inflammation becomes avail­
able on a wider scale. The present study reports the results 
of a direct comparison of m In-IgG scintigraphy to M‘In- 
WBC scintigraphy in a prospective study of patients with 
subacute infection.
PATIENTS AND METHODS 
Radiopharmaceuticals
Ind ium -1I1-W BC. Total WBC count and differentiation were 
determined. Forty to 50 ml of blood was drawn by venipuncture 
in a syringe containing 10 ml acid citrate dextrose (ACD). Under 
strictly sterile conditions, 6 ml 6 % hvdroxyethyl starch were 
added to 50 ml of ACD-blood. The erythrocytes were allowed to 
sediment for 1 hr. The supernatant was removed and centrifuged 
for 10 min at 150 g. The cell pellet was washed with 5 ml of a
1 % human serum albumin (HSA) solution in isotonic phosphate- 
buffered saline (PBS) buffer (pH = 7.4) and centrifuged once 
more for 10 min at 150 g. The cell pellet was resuspended in 1.5 
ml of a 1% HSA solution in isotonic PBS buffer. Twenty-five to 
30 MBq MIIn-oxine solution ( m In-oxine DRN 4908, Mallinck­
rodt Diagnostica Holland, Petten, The Netherlands) in 0.2 M  
Tris(hydroxymethyl)aminomethane (pH = 8.0) were added to 
the cell suspension and incubated for 30 min at room tempera­
ture. The cells were centrifuged a third time for 10 min at 150 g, 
the supernatant discarded and the cell pellet was resuspended in 
5 ml of a 1% HSA solution in isotonic PBS buffer. Morphologic 
integrity of the leukocytes was checked by light microscopic 
examination. Labeling efficiency, determined by measuring cell- 
associated and supernatant activity in a sample of the labeled 
WBC suspension, was always higher than 95%. A dose of 25-30 
MBq of 11'In-WBC was injected intravenously.
Ind ium -11 l-lgG . Diethylenetriaminepentaacetic bicyclic an­
hydride (bicyclic DTPA) was conjugated to HIV and HBsAg- 
negative, human, nonspecific, polyclonal IgG (Sandoglobulin, 
Sandoz AG, Nuernberg, FRG) according to the method described
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by Hnatowich and colleagues (6 ). Two to three DTPA ligands 
were coupled to one IgG molecule. The purified DTPA-conju- 
gated IgG was diluted to 2 mg/ml with 0.15 M  acetate (pH = 
6.5) and sterilized by membrane filtration. Aliquots of 0.5 ml of 
the conjugate were radiolabeled with '" In  (Indium chloride. 
Amersham International Ltd., Buckinghamshire, UK) via citrate 
transchelation. Radiochemical purity was determined by ITLC- 
SG chromatography (Gelman Laboratories, Ann Arbor, MI) with
0.1 M  citrate (pH = 5) as the solvent. Labeling efficiency was 
always higher than 95%. A dose of approximately 1 mg of IgG- 
labeled with 75 MBq " 'In  was injected intravenously.
Study Design
Since both radiopharmaceuticals were labeled with " 'In ,  the 
investigations had to be separated in time to allow clearance of 
the radiopharmaceutical that was administered first. The maxi­
mal '" In  dose that can be safely injected with leukocytes is 
limited to 30 MBq (7,8). This strict limitation of " 'In  does not 
apply to the administration of " 'In-IgG  (9). Therefore, in this 
study '"In-W B C  scintigraphy was performed first and " 'In-IgG  
scintigraphy 1 wk later; in that way adequate images of both 
radiopharmaceuticals could be obtained, while imaging times 
remained reasonable. Immediately before the administration of 
" 'In-IgG , the remaining activity of '"In-W B C  in the liver and 
the spleen region was determined and compared to the activity 
in the '"In-IgG  image that was obtained 4 hr postinjection.
Patients
Patients with normal or elevated peripheral leukocyte counts 
in whom " 'In-W B C  scintigraphy was indicated because of a 
suspected focal infection or inflammation were eligible for the 
study. Patients who did not have a stable medical condition for 
the interval between the two imaging techniques were excluded.
No patient had a history suggestive of IgA- or IgG-deficicncy 
or adverse reaction to previous IgG administration. Pregnant and 
lactating females were excluded. Informed consent was obtained 
from all patients. The study was approved by the Institutional 
Review Board of the University Hospital Nijmegen.
Thirty-five patients were studied ( 17 males, 18 females; mean 
age 51.8 yr, range 1 8 - 8 7  vr). The mean WBC count was 8.9 x 
10M /liter (range 3.6 -  19.0 x  101' /liter). The relative num ber of 
granulocytes was always higher than 60% ofthe  total WBC count. 
None of the patients was immunocompromised.
Three other patients were excluded from the study; one patient 
due to progressive disease, one patient due to regression of an 
infectious focus, and in the third patient the scintigraphic results 
could not be verified.
Imaging Procedures
Scintigraphic images were obtained with a Siemens Orbiter 
gamma-camera connected to a Scintiview image processor (Sie­
mens Inc., Hoffman Estates, IL). All images were collected in 
digital format in a 256 x  256 matrix. A medium-energv, parallcl- 
hole collimator (173 keV peak, 15% symmetric window; 247 keV 
peak, 15% symmetric window) was used.
Both " 'In-W B C  and " 'In-IgG  images were acquired at 4, 24 
and 48 hr postinjection for a preset time of 5, 7.5, and 10 min 
respectively. At least once, 24 hr postinjection, spot views of the 
total body were obtained.
The remaining " 'In-W B C  activity in the liver and spleen 
region, determined immediately before " 'In-IgG  injection, was 
always lower than 10% of the 1 "In-IgG activity in the same region 
on the image obtained 4 hr after " ‘In-IgG administration.
All images were interpreted by three observers blinded to the 
results of the verification procedures. An ' ' 'In-WBC scintigraphy 
was interpreted as positive if consistent, focally increased uptake 
was seen during the study, excluding known causes for artifacts. 
An " 'In-IgG  scan was interpreted as positive if focally increasing 
accumulation could be noted over time, since hypercmic nonin­
flamed lesions initially show some uptake but no further accu­
mulation of 1 "In-IgG over time (5).
The results o f the scintigraphic findings were verified by clini­
cal, roentgenological and ultrasonographic methods and, if pos­
sible, by bacterial cultures. The outcome of the two imaging 
techniques was analyzed, using the x : - test.
RESULTS
The clinical characteristics, scintigraphic results and 
verification procedures are summarized in the Tables 1 
and 2. Table 1 represents those patients with infections 
predominantly of the locomotor system; Table 2 those 
patients with other types of infection. All possible infec­
tions were either subacute—duration of illness for several 
weeks—or chronic—duration of illness for months or even 
years.
All lesions in the locomotor system (Table 1) were 
correctly identified with '"In-IgG scintigraphy. Two cases 
of arthritis and two cases of osteomyelitis were missed with 
"'In-WBC scintigraphy. One rib lesion on "'In-WBC 
scintigraphy could not be proven by other diagnostic tech­
niques. Figure 1 shows concordant "'In-IgG and " ‘In- 
WBC images of a soft-tissue infection caused by hemolytic 
Streptococci in Patient 9.
In Patient 15 (Table 2) abscesses in the liver, caused by 
Bacteroides J'ragil is, were seen on the '"In-WBC scintig­
raphy, while "'In-IgG was distributed homogeneously in 
the liver. This was the only patient with verified infectious 
foci, which were correctly identified with '"In-WBC, but 
missed with '"In-IgG scintigraphy.
Figure 2 represents the images of Patient 16 who has 
diverticulitis. With ‘"In-IgG scintigraphy, inflammatory 
activity w'as adequately detected, while ‘"In-WBC scintig­
raphy showed no abnormalities. In a splenectomized pa­
tient (no. 17) ‘"In-WBC scintigraphy indicated left-sided, 
subphrenic activity, while no elevated ‘"In-IgG uptake 
was seen. At surgery, neither abdominal infection nor 
accessory splenic tissue were found.
Figure 3 shows the images of Patient 32 who had renal 
failure due to polycystic kidneys and Escherichia coli 
infection of a renal cyst. There is increased " ‘In-IgG 
uptake, but no abnormal " ‘In-WBC accumulation.
Two patients had malignant tumors. In Patient 8, a 
mediastinal malignant non-Hodgkin's lymphoma was di­
agnosed. Patient 23 had an alveolar cell carcinoma of the 
lung and a malignant non-Hodgkin's lymphoma. The 
tumors did not show pathologic ‘"In-WBC or ‘"In-IgG 
accumulation.
When using lesions rather than patients, sensitivity and 
specificity in this group of patients was 74% and 100% for 
‘"In-IgG scintigraphy and 52% and 78% for " ‘In-WBC
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TABLE 1
Clinical Characteristics, Scintigraphy and Verification Results for Patients with Infections of the Locomotor System
Patient
Sex/
A
Scintigraphy Verification
Age
no. (WBCC) Duration Suspected focus WBC igG Proc. Result
1 F/79 2 mo Shoulder + + P \
(8.7) Knee + + P — MT infection
Lumbar spine + + P /
Total-hip prosthesis — — F, R no evidence of infection
2 F/59 2 mo Proximal femur + + S nonspecific osteomyelitis
(8.4) Lumbar spine — — P no infection
Femoral blood ves­ + — F no evidence of infection or
sels thrombosis
3 F/51
(6.4)
3 mo Sternum F, R. C no evidence of persisting infec­
tion
4 M/54
(13.1)
10 yr Tibia + + F, R osteomyelitis of tibia (productive 
fistula)
5 M/32
(11.1)
1 yr Delayed healing of 
tibial fracture
S noninfected osteosynthesis after 
tibial fracture
6 F/43
(7.5)
2 mo Toe 1 + C, R SA osteomyelitis of toe
7 F/87 2 wk Knee — + P synovitis
(4.9) Total-hip prosthesis — — F, R no evidence of infection
8 M/34
(6.6)
4 wk Sternum + C, R, F SM osteomyelitis
9 F/61
(15.6)
3 wk Upper leg/pelvic 
soft tissues
+ + P HS infection
10 F/76
(11.7)
4 mo Total-hip prosthesis F, R no evidence of infection
11 F/66 6 wk Thoracic spine -1- + P HS infection
(4.7) Hip — + P HS infection
12 F/27
(3.6)
3 wk Shoulder + + S SA arthritis
13 M/60 3 wk Upper leg + + S \
(17.2) Shoulder + + S — SA infection
Foot + P /
14 F/67
(4.9)
9 mo Total-hip prosthesis — F, R no evidence of infection
WBCC = white blood cell count ( x l0 9/liter). C = bacterial cultures; E = endoscopy; F = clinical follow-up of at least 3 mo; P = puncture/ 
biopsy; R = roentgenologic procedures, including CT scanning and ultrasonography; S = surgery; BF = Bacteroides fragilis, CA = Candida 
albicans; EA = Enterobacter aerogenes; EC = Escherichia coli; HS = ß-hemolytic streptococcus; MT = Mycobacterium tuberculosis; SA = 
Staphylococcus aureus\ SM = Streptococcus mitis; and SP = Streptococcus pneumoniae.
scintigraphy, respectively. The differences between the two 
techniques are significant (x2 = 6.50, p < 0.01).
DISCUSSION
The results of the present prospective comparative study 
indicate th a t11 ‘In-IgG scintigraphy performed significantly 
better than '"In-WBC scintigraphy in this group of pa­
tients with subacute infections. The majority of the de­
tected infections was localized in the locomotor system. 
The usefulness of ‘"In-IgG scintigraphy for the detection 
of infections of the locomotor system corroborates the 
results in a previous study from our group in which no 
comparison was made with ‘"In-WBC scintigraphy (5). 
The relatively poor performance of "'In-WBC scintigra­
phy in subacute infectious bone and joint disease is in 
agreement with the findings of other authors (7,70,77).
The scintigraphic result in the patient with liver ab­
scesses cannot be explained satisfactorily. A possible ex­
planation for the normal "'In-IgG images could be that 
the degree of inflammation decreased with treatment (a 
daily dose of 2 g of metronidazole intravenously).
The performance o f 111 In-IgG scintigraphy in abdominal 
infections is in agreement with data in the literature (2 ). 
Although accessory splenic tissue was not found at surgery 
in the splenectomized patient, it could have been the cause 
for the false-positive "'In-WBC scintigraphy. Unfortu­
nately, ‘,t,mTc-sulphur colloid scintigraphy could not be 
performed.
Both " ‘In-WBC and " ‘In-IgG scintigraphy missed a 
case of endocarditis. This was not surprising since ‘"In- 
IgG shows a physiologic high blood-pool activity in all 
patients, thereby obscuring possible cardiac lesions. More­
over, these small lesions show only mild inflammation.
In four patients with vascular lesions, ‘"In-WBC scin­
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TABLE 2
Clinical Characteristics of Scintigraphy and Verification Results for Patients with Other Types of Infection
Patient
no.
Sex/
Age
(WBCC)
Scintigraphy Verification
Duration Suspected focus WBC igG Procedure Result
15 M/23
(8.8)
1 mo Liver + — R, C multiple BF liver ab­
scesses
16 F/80
(5.7)
3 wk Lower abdomen + E diverticulitis of the sigmoid
17 F/32
(8.9)
1 mo Abdomen, persisting infection 
after splenectomy
+ S no infection, no accessory 
splenic tissue
18 F/42
(10.9)
1 mo Abdomen m^mm S polycystic ovaries, no in­
fection
19 M/49
(5.1)
1 mo Treated EC sepsis, no focus ■ F, C, R no evidence of persisting 
infection
20 F/65
(5.0)
6 mo Fever of unknown origin “* F, C, R no cause identified
21 M/27
(5.6)
1 yr Fever of unknown origin F. C, R no infectious focus identi­
fied, fever of hypothal­
amic origin
22 M/60
(10.2)
4 wk Fever of unknown origin F . R . C no cause identified
23 M/76
(5.3)
4 wk Fever of unknown origin F, C, R no evidence of infection, 
fever caused by malig­
nant lymphoma or 
lungcarcinoma
24 M/81
(10.8)
4 wk Endocarditis 
Femoral blood vessels
Rib
+
+
—
C, R 
F
F, R
EA infection
no evidence of infection or 
thrombosis 
no evidence of infection
25 F/42
(8.8)
6 mo Aorto-bifemoral 
Vascular graft
S infected graft (intestinal 
bacteria)
26 F/22
(9.2)
6 wk Pulmonary tuberculosis 
Hilar lymph node involvement + —
C, R 
R. F
primary MT infection up­
per lobe of left lung 
no evidence of lymph 
node involvement
27 M/38
(11.1)
4 wk Pulmonary tuberculosis + + C, R primary MT infection up­
per lobe of both lungs
28 M/30
(19.0)
6 wk Pulmonary tuberculosis + + C, R primary MT infection both 
lungs
29 M/59
(6.6)
6 wk Pulmonary tuberculosis
" "
C, R miliary MT infection of 
lungs
30 F/55
(8-9)
1 mo Eye (prior to scintigraphy: 
surgical and medical treat­
ment for CA endophthalmi­
tis)
F no evidence of persisting 
infection
31 M/75
(114)
3 wk Eye
Shoulder
+ S
P
SP endophthalmitis 
no evidence of infection
32 M/58
(10.4)
2 wk Polycystic kidneys + C, F EC infection of renal cyst
33 F/59
(6.1)
2 mo Polycystic kidneys 
Treated pyelonephritis of 
renal transplant
— —
F, C 
F, C, P
no evidence of infection 
no evidence of persisting 
infection
34 M/25
(7.2)
3 wk Positive yersinia serology, no 
focus
F, R no focus identified
35 M/18
(10.7)
See Table 1 for definitions
1 yr
•
Positive yersinia serology, no 
focus
F, R no focus identified
tigraphy showed two sites of accumulation in the femoral 
vein or artery. Since clinical examination and follow-up 
ruled out infection or thrombosis, the two lesions had to 
be considered false-positives. Both techniques apparently
missed a low-grade infection of a vascular graft. However, 
data in the literature suggest that 11'In-IgG scintigraphy is 
a good technique for evaluation of vascular graft infection
(4).
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FIGURE 1. Concordant 1111n-IgG and in ln-WBC scintigra­
phies: soft tissue infection of the upper left leg (large arrows), 
extending to the bladder region (small arrows), in Patient 9, 
due to hemolytic streptococci. (A )1111n-IgG scintigraphy, posterior 
view of the pelvis, 48 hr postinjection. (B )1111n-WBC scintigraphy, 
posterior view of the pelvis, 48 hr postinjection.
Both techniques showed variable results in the delinea­
tion of tuberculous infection. Large lesions were ade­
quately detected, whereas small infectious foci were 
missed. One probable explanation for the negative WBC 
scintigraphies is that lymphocytes and macrophages, rather 
than granulocytes, are involved in a tuberculosis infection.
The detection of an infected renal cyst with "'In-IgG 
was only possible because this patient had renal failure 
and was on hemodialysis. In patients with normal renal 
function, it will be nearly impossible to delineate infection 
in the kidneys, since the physiologic "'In-IgG uptake in 
kidneys will most probably obscure pathologic accumula­
tion. The utility of '"In-IgG scintigraphy for detection of 
infectious foci in uremic patients is not well established. 
Tolkoff and Rubin suggest that under these circumstances 
' "In-IgG accumulation in infectious foci is poor ( 12).
The normal scintigraphy of the two patients with active 
disseminated yersiniosis can probably be explained accord­
ing to the literature by the small size of the infectious foci 
and the localization in mesenteric lymphnodes and par­
enchymatous organs (13). Detection of such small lesions 
with moderately increased activity is not possible due to a 
relatively poor target/non-target ratio and to the limited
FIGURE 2. True-positive 1111n-IgG scintigraphy and false-neg- 
ative 111ln-WBC scintigraphy: diverticulitis of the sigmoid, proven 
at endoscopy, in Patient 16. (A) 1111n-IgG scintigraphy, anterior 
view of the pelvis, 48 hr post-postinjection: increased 111 In-IgG 
uptake in the lower left abdomen (arrow). (B) 1,1 In-WBC scintig­
raphy, anterior view of the pelvis, 48 hr postinjection: no abnormal 
accumulation of activity in the abdomen.
resolution of the gamma camera, especially when localized 
in organs with relatively high physiologic activity uptake 
such as liver and kidneys.
The subacute nature of the infections we studied, in 
many patients not accompanied by leukocytosis, could 
partially explain the relatively large number of false-nega­
tive '"In-WBC results. The number of WBC appears not 
to be a major factor in ' "In-IgG accumulation, since '"In- 
IgG accumulated in infectious foci in granulocytopenic 
patients ( 14).
Indium- 1 1 1-WBC have a half-life in the circulation of 
approximately 6 hr ( 75). This fast blood clearance results 
in low background activity. With '"In-IgG scintigraphy, 
target-to-background ratios were lower due to the relatively 
slower blood clearance of "'In-IgG (V/i approximately 24 
hr) (5). However, this did not significantly interfere with 
image interpretation at 24 and 48 hr.
When designing the comparative study, several options 
were considered. A random sequence of the two techniques 
would have been the best choice. This was reluctantly 
rejected for a number of reasons. The " ‘In dose that can 
be safely injected with leukocytes is limited to 30 MBq
FIGURE 3. True-positive 11'In-IgG scin­
tigraphy and false-negative 111ln-WBC 
scintigraphy: Escherichia coli infection of 
a cyst in the left kidney of Patient 32 with 
renal failure due to polycystic kidneys. The 
patient was on hemodialysis. (A) 99mTc- 
mercaptoacetyltriglycine scintigraphy, 
posterior view of the kidneys, 15 min post­
injection: identification of residual kidney 
function. Note: no functional kidney tissue 
in the lower pole of the left kidney (arrow).
(B) 111 In-IgG scintigraphy, posterior view, 
48 hr postinjection: increased uptake in 
the lower pole of the left kidney (arrow).
(C )1111n-WBC scintigraphy, posterior view, 
48 hr postinjection: absence of accumula­
tion of activity in the renal regions.
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because of possible chromosomal damage to long-lived T- 
lymphocytes and the radiation burden to the spleen (7,8). 
Biodistribution and kinetic studies showed that this strict 
limitation does not apply to the administration of 11'In- 
IgG (9). If one would choose to perform the investigations 
in a random sequence, it would be necessary to lower the 
injected "'In-IgG dose to approximately 15 MBq for the 
first investigation. This would lead to unacceptably long 
imaging times or to statistically inadequate images. Injec­
tion of the full dose of 75 MBq ' "In-IgG before the '"In- 
WBC scintigraphy would increase the time span between 
the two studies to at least 2 wk in order to avoid significant 
"'In-IgG contribution to the '"In-WBC images. More­
over, "'In-WBC scintigraphy, being the standard proce­
dure, was considered to be of clinical importance and 
therefore was accepted in the final study design as the first 
procedure. In the current study, there was no significant 
contribution o f 1 "In-WBC activity in the 1 "In-IgG images.
When comparing ' "In-WBC and 1 "In-IgG scintigraphy 
in a fixed sequence, the two investigations had to be 
separated in time. This introduces some inevitable bias. 
Indium-111-Ig scintigraphy was systematically placed in a 
disadvantageous position, since many patients were treated 
for a longer period of time. Only patients with disease in 
a relatively stable and subacute condition were eligible for 
the study. Patients with acute infections, who required 
immediate invasive therapy after completion o f 111 In-WBC 
scintigraphy, were not studied in this protocol. Neverthe­
less, we feel that our patients are representative candidates 
for such imaging procedures, since a major indication for 
these scintigraphic techniques is localization of chronic 
infection. While data in the literature as well as our own 
experience suggest that acute infections can be adequately 
detected with both '"In-WBC and " ‘In-IgG scintigraphy 
(2,76), clinical examination and other imaging techniques 
are usually sufficient.
Alternatives for comparative studies between WBC and 
IgG scintigraphy would be to label one of the two phar­
maceuticals with ^ mTc. Buscombe et al. found that g9mTc- 
IgG and ‘"In-WBC scintigraphy showed excellent con­
cordance (17). In this study, the authors co-injected both 
radiopharmaceuticals. They did not provide information 
as to whether " ‘In scatter in the 99mTc window at 24 hr 
postinjection could have possibly contributed to some 
extent to the concordance between the two techniques at 
24 hr postinjection. In their study protocol, "'In-WBC 
scintigraphy was the gold standard. In our study, we found
13 false-negative with " ‘In-WBC scintigraphy, mainly in 
patients with low-grade bone and joint infections. An 
important question is whether gwmTc-labeled IgG performs 
equally to ‘"In-IgG. In artificially induced calf muscle 
abscesses in rats, we found that lWmTc-labeled IgG shows 
relatively poor uptake when compared to ‘ ' 1 In-IgG uptake, 
although target/non-target ratios were similar (18). An­
other alternative for comparing 1 ' 'In-IgG scintigraphy with 
labeled WBC could be 99mTc-labeling of WBCs. Techne­
tium-99m-hexamethylpropyleneamine-oxime (HMPAO) 
labeled WBCs seems to be a useful technique for labeling 
leukocytes with gt,mTc and appears promising in chronic 
infectious disease in humans (19-21). However, a disad­
vantage of this technique is that rapid biliary excretion of 
w‘,mTc-HMPAO interferes with interpretation of abdominal 
images obtained later than 2-3 hr postinjection. The 99mTc- 
colloid labeling of leukocytes in whole blood is poorly 
established (22-24). A major limitation of every radio­
pharmaceutical labeled with ggmTc is that imaging beyond 
24 hr after injection is impossible.
Although Ga has been used successfully in the evalu­
ation of patients with subacute and chronic illness, the 
multi-peak high energy gamma rays, the physiologic bowel 
excretion and the nonspecific uptake in tumors and in 
areas of increased bone turnover make '' Ga-citrate a less 
optimal radiopharmaceutical for delineating infection (77, 
27).
The mechanism of "'In-IgG accumulation is not fully 
elucidated as yet. Increased vascular permeability and 
nonspecific macromolecular entrapment in inflammatory 
foci is the most probable hypothesis (14,25). Notwith­
standing the uncertainty of the mechanism of accumula­
tion of IgG, the present study shows that ' 1 'In-IgG scintig­
raphy performs significantly better in patients with sub­
acute infections than ' "In-WBC scintigraphy. In addition, 
‘"In-IgG is a more convenient radiopharmaceutical in 
that it is readily available as a sterile, pyrogen-free kit for 
fast labeling, obviating the need for handling the patient’s 
blood or a 3-hr labeling procedure. Moreover, since IgG is 
a human protein, there is no risk for the development of 
human anti-mouse antibodies that may cause side effects 
(26,27).
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